All In Biotech

Drug Trial Radar · NCT07743723

A Study of IOV-5001 in Adults With Advanced Solid Tumors

A Phase 1/2, Multicenter, Multi-cohort, Open-label Study of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen With IOV-5001 in Participants With Previously Treated Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2034

Study completion Mar 2044

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors

Conditions

  • Advanced Solid Tumors
  • Non-Small Cell Lung Cancer
  • Triple Negative Breast Cancer (TNBC)
  • Colorectal Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Metastatic Solid Tumors
  • Unresectable Solid Tumor

Interventions

  • IOV-5001Biological

    IOV-5001 will be administered as 2 infusions, which will be administered in a hospital setting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Safety AssessmentTime frame: Up to 30 days
  2. Phase 2: Efficacy Measured by Overall Response Rate (ORR)Time frame: Up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medicine-New York Presbyterian Hospital

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.